DiaMedica Therapeutics Inc. Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current
DiaMedica Therapeutics Inc. (DMAC) had Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current of $250.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent · last filed 2026-03-30
- 2025-12-31: Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current $250.00K.
- 2024-12-31: Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current $235.00K.
| Period end | Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $250.00K 10-K · filed 2026-03-30 |
| 2024-12-31 | $235.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |